MDCO The Medicines Company

53.09
+0.9  (+2%)
Previous Close 52.19
Open 52.15
Price To Book 110.59
Market Cap 4,212,297,245
Shares 79,350,047
Volume 1,049,542
Short Ratio
Av. Daily Volume 2,328,111
Stock charts supplied by TradingView

NewsSee all news

  1. The Medicines Company to Participate in the Chardan 3rd Annual Genetic Medicines Conference

    The Medicines Company (NASDAQ:MDCO) announced that it will participate in the Chardan 3rd Annual Genetic Medicines Conference on Tuesday, October 8, 2019, in New York. The Company is scheduled to participate in a

  2. The Medicines Company Announces Positive Topline Results for ORION-10 Phase 3 Study of Inclisiran in ASCVD Patients

    ­ ORION-10 study met all primary and secondary endpoints, with durable and potent efficacy and excellent safety of inclisiran that were at least as favorable as observed in ORION-11 ­ ORION-10 completion marks

  3. The Medicines Company Announces Positive Topline Results for ORION-9 Phase 3 Study of Inclisiran in Heterozygous Familial Hypercholesterolemia Patients

    ­ ORION-9 study met all primary and secondary efficacy endpoints ­ Inclisiran demonstrated durable and potent efficacy and excellent safety in a patient population where cardiovascular disease is most severe ­

  4. The Medicines Company Presents Results from ORION-11, First Phase 3 Trial of Inclisiran, Showing Durable and Potent Lowering of LDL-C with Twice-Yearly Dosing

    -  Inclisiran achieved 54% LDL-C lowering with time-adjusted reductions of 50% sustained over 18 months of treatment -  ORION-11 study demonstrates inclisiran's excellent safety profile, including no treatment-related

  5. The Medicines Company Announces Positive Topline Results from First Pivotal Phase 3 Trial of Inclisiran

    ­ ORION-11 study met all primary and secondary efficacy endpoints with efficacy consistent with Phase 1 and 2 studies ­ Safety profile of inclisiran was at least as favorable as in ORION-1 Phase 2 and ORION-3

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 data met all endpoints - September 25, 2019.
Inclisiran - ORION-9
Hypercholesterolemia
Development discontinued due to poor effiacy - November 7, 2016.
MDCO-216 - MILANO-PILOT
Acute coronary syndrome (ACS)
Approved August 29, 2017.
Meropenem-vaborbactam
Complicated urinary tract infections (cUTI)
CRL April 30 2014. Approved June 22 2015
Cangrelor
Reduction of thrombotic cardiovascular events including stent thrombosis in patients with coronary artery disease undergoing percutaneous coronary intervention (PCI)
Approved April 30, 2015.
IONSYS
Acute postoperative pain
Approved August 6 2014 under priority review.
Oritavancin
ABSSSI
Phase 3 trial to be initiated 1H 2018.
Inclisiran
Homozygous familial hypercholesterolemia (HoFH)
Phase 3 data met all endpoints - September 25, 2019.
Inclisiran - ORION-10
Cardiovascular disease (ASCVD)
Phase 3 trial met all primary and secondary efficacy endpoints. Noted September 2, 2019 a 54% LDL-C lowering after 11 months and 50% over 18 months.
Inclisiran - ORION 11
Cardiovascular disease (ASCVD)
Phase 2 open-label data presented May 18, 2019. 51% decrease in LDL-C levels.
Inclisiran - ORION 3
Cardiovascular disease (ASCVD)

Latest News

  1. The Medicines Company to Participate in the Chardan 3rd Annual Genetic Medicines Conference

    The Medicines Company (NASDAQ:MDCO) announced that it will participate in the Chardan 3rd Annual Genetic Medicines Conference on Tuesday, October 8, 2019, in New York. The Company is scheduled to participate in a

  2. The Medicines Company Announces Positive Topline Results for ORION-10 Phase 3 Study of Inclisiran in ASCVD Patients

    ­ ORION-10 study met all primary and secondary endpoints, with durable and potent efficacy and excellent safety of inclisiran that were at least as favorable as observed in ORION-11 ­ ORION-10 completion marks

  3. The Medicines Company Announces Positive Topline Results for ORION-9 Phase 3 Study of Inclisiran in Heterozygous Familial Hypercholesterolemia Patients

    ­ ORION-9 study met all primary and secondary efficacy endpoints ­ Inclisiran demonstrated durable and potent efficacy and excellent safety in a patient population where cardiovascular disease is most severe ­

  4. The Medicines Company Presents Results from ORION-11, First Phase 3 Trial of Inclisiran, Showing Durable and Potent Lowering of LDL-C with Twice-Yearly Dosing

    -  Inclisiran achieved 54% LDL-C lowering with time-adjusted reductions of 50% sustained over 18 months of treatment -  ORION-11 study demonstrates inclisiran's excellent safety profile, including no treatment-related

  5. The Medicines Company Announces Positive Topline Results from First Pivotal Phase 3 Trial of Inclisiran

    ­ ORION-11 study met all primary and secondary efficacy endpoints with efficacy consistent with Phase 1 and 2 studies ­ Safety profile of inclisiran was at least as favorable as in ORION-1 Phase 2 and ORION-3